Kalinina, Nadezhda, RM Analytics
| Issue | Section | Title | Abstract | File |
| No 2 (2021) | Articles | Russian pharmaceutical market as of the first quarter, 2021 | Abstract |
 (Rus) |
| No 2 (2021) | Articles | A review of tender purchases of L01 group – antineoplastic agents | Abstract |
(Rus) |
| No 1 (2021) | Articles | Russian pharmaceutical market at the end of 2020 | Abstract |
(Rus) |
| No 3 (2021) | Articles | Glycemia under control | Abstract |
(Rus) |
| No 9 (2020) | Articles | The market is driven by the public sector | Abstract |
(Rus) |
| No 9 (2020) | Articles | Public procurement during coronavirus pandemic. Review of tender purchases of J05 Direct-acting antivirals under FZ-44 and FZ-223 | Abstract |
(Rus) |
| No 10 (2020) | Articles | Pharmacy market for 9 months 2020: coronavirus and digital | Abstract |
(Rus) |
| No 10 (2020) | Articles | AnviMax®: optimal drug to combat ARVI and influenza | Abstract |
(Rus) |
| No 11-12 (2020) | Articles | Modern anticoagulant therapy in atrial fibrillation patients | Abstract |
(Rus) |
| No 11-12 (2020) | Articles | Anticoagulant group tender review | Abstract |
(Rus) |
| No 11-12 (2020) | Articles | Affordable and modern antithrombotic therapy for atrial fibrillation | Abstract |
(Rus) |